{"sentence_labels": [1, -1, -1, -1], "text": "From June 2013 through September 2014, a total of 37 eligible participants were enrolled and randomized in a 3.5 to 1 ratio to receive omalizumab (N=29) or placebo (N=8) in conjunction with peanut oral immunotherapy (OIT). The selected randomization ratio was based on the power analysis and on the strong therapeutic effect of omalizumab observed in previous open-label studies. The study design called for 28 patients in the omalizumab arm, but one participant randomized to omalizumab withdrew before receiving the first injection and was replaced per the protocol. Dosing for omalizumab (and placebo) was in accordance with the Xolair Global Dosing Schedule with slight modification.", "section": "Randomization and Treatment", "classification_label": 0, "section_number": 4, "sentences": ["From June 2013 through September 2014, a total of 37 eligible participants were enrolled and randomized in a 3.5 to 1 ratio to receive omalizumab (N=29) or placebo (N=8) in conjunction with peanut oral immunotherapy (OIT).", "The selected randomization ratio was based on the power analysis and on the strong therapeutic effect of omalizumab observed in previous open-label studies.", "The study design called for 28 patients in the omalizumab arm, but one participant randomized to omalizumab withdrew before receiving the first injection and was replaced per the protocol.", "Dosing for omalizumab (and placebo) was in accordance with the Xolair Global Dosing Schedule with slight modification."], "doc_id": "35186"}